Momenta Pharmaceuticals, Inc.

Janssen Biotech, Inc.

Nathaniel J Washburn

Carlos J Bosques

James Meador, Iii

Brian Edward Collins

Dorota A Bulik

Jonathan C Lansing

David J King

Ishan Capila

Naveen Bhatnagar

Cuihua Liu

Daniel Ortiz

Laura Rutitzky

Xiao-Jin Xu

Jennifer Murphy

Jay Duffner

Julia Brown

Lynn Markowitz

Sathya Prabbhakar

Hetal Sarvaiya

Enrique Arevalo

Kevin Millea

Maurice Gaston Hains

Sean Smith

Leona E Ling

Ian Christopher Parsons

Marilyn Kehry

Xiangping Zhu

Sucharita Roy

Anthony Manning

Victor Farutin

Jan Hillson

Patrick Halvey

Kevin McConnell

James Iii Meador

Robin Meccariello

The present disclosure relates to engineered IgG Fc constructs and uses thereof.

Compositions and methods related to engineered Fc constructs

The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

FcRn antibodies and methods of use thereof

The present invention relates to engineered IgG Fc constructs and uses thereof.

Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.

Modified glycoproteins

Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.

Methods of producing recombinant therapeutic fusion proteins described herein can include culturing Chinese hamster ovary (CHO) cells under conditions suitable for expression of a recombinant therapeutic fusion protein including one or more glycans, where the CHO cells have not been genetically engineered to produce terminal alpha-galactosyl residues on glycans; treating the one or more glycans of the recombinant glycoprotein with one or more exoglycosidases; measuring glycans containing terminal galactose-alpha-1-3-galactose residues on the fusion protein by nuclear magnetic resonance (NMR); and producing a recombinant therapeutic fusion protein in the CHO cells if a target level of terminal galactose-alpha-1-3-galactose residues is measured.

Galactose-alpha-1, 3-galactose-containing n-glycans in glycoprotein products derived from CHO cells

The present invention provides methods of evaluating a glycoprotein preparation for the absence, presence or amount of an N-acetylhexosamine glycan, e.g., an N-acetylglucosamine glycan.

N-acetylhexosamine-containing N-glycans in glycoprotein products

The present invention provides methods of evaluating CHO cells.

Gal &#x3b1;1-3gal-containing N-glycans in glycoprotein products derived from CHO cells

The present disclosure provides, among other things, methods for the identification of sulfated glycans in a mixture of glycans.

MS methods to evaluate glycans

Growing community of inventors

Littleton, MA, United States of America

Nathaniel J Washburn